Literature DB >> 3781625

Characterization of immune response to oral administration of Streptococcus sobrinus ribosomal preparations in liposomes.

R L Gregory, S M Michalek, G Richardson, C Harmon, T Hilton, J R McGhee.   

Abstract

Gnotobiotic rats gastrically intubated with a total of 12.5 micrograms of Streptococcus sobrinus ribosomal protein incorporated into cholesterol-based liposomes had significantly (P less than or equal to 0.01) fewer carious lesions on their molar surfaces than did nonimmunized infected controls after challenge with a virulent organism. The immunized animals had significantly (P less than or equal to 0.01) lower numbers of molar-adherent S. sobrinus cells and higher levels of salivary immunoglobulin A antibodies to S. sobrinus whole cells and ribosomes than did the control group. Dose-response studies indicated that 12.5 micrograms of S. sobrinus ribosomal protein in liposomes induced slightly higher immune responses than did 62.5, 125.0, and 250.0 micrograms of ribosomal protein incorporated into liposomes. Intubation of rats with up to 250.0 micrograms of S. sobrinus ribosomal protein alone was no more effective in reducing the numbers of molar-adherent S. sobrinus cells than were nonimmunized infected controls, establishing that insertion of ribosomes into liposomes was required for inducing an effective immune response. These results indicate that oral administration of as little as 12.5 micrograms of S. sobrinus ribosomal protein incorporated into liposomes can protect rats from caries formation after challenge with the virulent organism by inducing specific salivary immunoglobulin A antibodies which can inhibit colonization by the challenged S. sobrinus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3781625      PMCID: PMC260237          DOI: 10.1128/iai.54.3.780-786.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  The use of plastics in the design of isolator systems.

Authors:  P C TREXLER
Journal:  Ann N Y Acad Sci       Date:  1959-05-08       Impact factor: 5.691

2.  Association of Streptococcus mutants with human dental decay.

Authors:  W J Loesche; J Rowan; L H Straffon; P J Loos
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

3.  Ingestion of Streptococcus mutans induces secretory immunoglobulin A and caries immunity.

Authors:  S M Michalek; J R McGhee; J Mestecky; R R Arnold; L Bozzo
Journal:  Science       Date:  1976-06-18       Impact factor: 47.728

4.  Biochemical and serological properties of Streptococcus mutans from various human and animal sources.

Authors:  B Perch; E Kjems; T Ravn
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-06

5.  Purification and properties of dextransucrase from Streptococcus sanguis.

Authors:  J Carlsson; E Newbrun; B Krasse
Journal:  Arch Oral Biol       Date:  1969-05       Impact factor: 2.633

6.  Origin and differentiation of lymphocytes involved in the secretory IgA responses.

Authors:  J J Cebra; P J Gearhart; R Kamat; S M Robertson; J Tseng
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1977

7.  Antigens in Streptococcus mutans cross reactive with human heart muscle.

Authors:  I Van de Rijn; A S Bleiweis; J B Zabriskie
Journal:  J Dent Res       Date:  1976-04       Impact factor: 6.116

8.  Effective immunity to dental caries: protection of gnotobiotic rats by local immunization with Streptococcus mutans.

Authors:  S M Michalek; J Webb; J M Navia; A F Rahman; D W Legler
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

9.  Effects of local immunization with glucosyltransferase fractions from Streptococcus mutans on dental caries in rats and hamsters.

Authors:  M A Taubman; D J Smith
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

10.  Virulence of Streptococcus mutans: cariogenicity of S. mutans in adult gnotobiotic rats.

Authors:  S M Michalek; J R McGhee; T Shiota; D Devenyns
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

View more
  7 in total

1.  Novel asparagine-derived lipid enhances distearoylphosphatidylcholine bilayer resistance to acidic conditions.

Authors:  Adelphe M Mfuh; Mathew P D Mahindaratne; Maritza V Quintero; Frederick J Lakner; Ande Bao; Beth A Goins; William T Phillips; George R Negrete
Journal:  Langmuir       Date:  2011-03-17       Impact factor: 3.882

Review 2.  Oral microbial ecology and the role of salivary immunoglobulin A.

Authors:  H Marcotte; M C Lavoie
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

3.  Liposomes containing anti-idiotypic antibodies: an oral vaccine to induce protective secretory immune responses specific for pathogens of mucosal surfaces.

Authors:  S Jackson; J Mestecky; N K Childers; S M Michalek
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

4.  Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid.

Authors:  C A Guzman; G Molinari; M W Fountain; M Rohde; K N Timmis; M J Walker
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

5.  Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.

Authors:  Shinobu Watarai; Tana Iwase; Tomoko Tajima; Eiji Yuba; Kenji Kono
Journal:  ScientificWorldJournal       Date:  2013-02-04

6.  Induction of antibody response in the oral cavity of dogs following intraocular (eye drop) immunization with Porphyromonas gingivalis cell lysate incorporated in pH-sensitive fusogenic polymer-modified liposomes.

Authors:  Yosuke Shimizu; Tadashi Iwasaki; Tomoko Tajima; Eiji Yuba; Kenji Kono; Shinobu Watarai
Journal:  J Vet Med Sci       Date:  2016-12-05       Impact factor: 1.267

7.  Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.

Authors:  Seiji Okazaki; Tadashi Iwasaki; Eiji Yuba; Shinobu Watarai
Journal:  J Vet Med Sci       Date:  2017-12-28       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.